NICE recommends further treatment option for underserved heart failure population

In reversal of its initial recommendation, NICE has issued final draft guidance recommending empagliflozin (Jardiance) as an option for adults with symptomatic chronic heart failure with preserved or mildly reduced ejection fraction.

by Chloe Harman

To continue enjoying this article, please sign in. You can register for free for limited further access, or subscribe now for full access to all our content. View our subscription and registration options.

Sign In

Trouble signing in?

Reset password: Click here

Need help? Email us



  • Limited free articles a month 
  • Free email bulletins

Register Now

Take a 30-day trial

  • Join MIMS now and pay nothing for the first 30 days

Sign Up